Nola M. Hylton

Also affiliated with University of California System

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

9.2Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 53 papers — median percentile 93. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1

Scientific Data(2022)10.1038/s41597-022-01555-4

Top 7%

3.4DataRank

Top 7%18 citations

Sarthak Pati, Megh Bhalerao, Siddhesh Thakur, Nariman Jahani, Vivian Belenky +7 more

Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial

Radiology(2020)10.1148/radiol.2020202465

N/A

1.8DataRank · unranked

43 citations

Justin Romanoff, Habib Rahbar, Averi E. Kitsch, Sara Harvey, Jennifer G. Whisenant +18 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge

Radiology Imaging Cancer(2024)10.1148/rycan.230033

Top 23%

0.878DataRank

Top 23%25 citations

Savannah C. Partridge, David C. Newitt, Jon A. Steingrimsson, Helga S. Marques, Patrick J. Bolan +27 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Development, standardization, and testing of a lexicon for reporting contrast‐enhanced breast magnetic resonance imaging studies

Journal of Magnetic Resonance Imaging(2001)10.1002/jmri.1127

N/A

0.829DataRank · unranked

251 citations

Nola M. Hylton, Karen Kinkel, Mary G. Hochman, Christiane K. Kuhl, Werner A. Kaiser +7 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

npj Breast Cancer(2020)10.1038/s41523-020-00203-7

N/A

0.666DataRank · unranked

84 citations

David C. Newitt, Jessica Gibbs, Lisa J. Wilmes, Ella F. Jones, Vignesh A. Arasu +57 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0.598DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response

Radiology(2021)10.1148/radiol.2021203645

N/A

0.550DataRank · unranked

38 citations

Wen Li, David C. Newitt, Roy Harnish, Fredrik Strand, Alex Nguyen +56 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0.494DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer

Tomography(2020)10.18383/j.tom.2020.00016

N/A

0.489DataRank · unranked

25 citations

David C. Newitt, Bo La Yun, Ella F. Jones, Vignesh A. Arasu, Lisa J. Wilmes +8 more

Repeatability of Quantitative MRI Measurements in Normal Breast Tissue

Translational Oncology(2014)10.1593/tlo.13841

N/A

0.477DataRank · unranked

23 citations

Ella F. Jones, Ania Azziz, John Kornak, Lisa J. Wilmes, David C. Newitt +7 more

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET

Scientific Reports(2020)10.1038/s41598-020-78865-3

N/A

0.464DataRank · unranked

21 citations

Wen Li, Youngho Seo, Robert R. Flavell, John Kornak, Benjamin L. Franc +5 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study

Tomography(2020)10.18383/j.tom.2019.00025

N/A

0.442DataRank · unranked

18 citations

David C. Newitt, Ghoncheh Amouzandeh, Lisa J. Wilmes, Ek T. Tan, Luca Marinelli +8 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial

Tomography(2020)10.18383/j.tom.2020.00006

N/A

0.434DataRank · unranked

17 citations

Wen Li, Jessica Gibbs, Lisa J. Wilmes, Alex Nguyen, Ella F. Jones +7 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0.406DataRank · unranked

14 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment

Radiology Imaging Cancer(2023)10.1148/rycan.220126

N/A

0.373DataRank · unranked

8 citations

Teffany Joy Bareng, Jessica Gibbs, Wen Li, Elissa R. Price, Bonnie N. Joe +93 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0.345DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial

Translational Oncology(2022)10.1016/j.tranon.2022.101411

N/A

0.312DataRank · unranked

7 citations

Eric A. Cohen, Nariman Jahani, Susan P. Weinstein, Lauren Pantalone, Nola M. Hylton +5 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0.300DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0.297DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy

Radiology Imaging Cancer(2024)10.1148/rycan.230082

N/A

0.208DataRank · unranked

3 citations

Natsuko Onishi, Deep Hathi, Courtney Lawhn-Heath, John Kornak, Wen Li +12 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0.165DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0.165DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0.104DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

npj Breast Cancer(2025)10.1038/s41523-025-00830-y

N/A

0.104DataRank · unranked

1 citations

Karen S. Flatten, Taylor M. Weiskittel, Annapoorna Venkatachalam, Annabella R. Strathman, Olivia K. Rossman +17 more

Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial

Tomography(2020)10.18383/j.tom.2020.00008

N/A

0DataRank · unranked

17 citations

Ghoncheh Amouzandeh, Savannah C. Partridge, Helga S. Marques, B. Herman, Brian D. Ross +4 more

Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702)

Journal of Breast Imaging(2020)10.1093/jbi/wbaa103

N/A

0DataRank · unranked

18 citations

Justin Romanoff, Habib Rahbar, Averi E. Kitsch, Sara Harvey, Linda Moy +17 more

Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ

npj Breast Cancer(2024)10.1038/s41523-024-00677-9

N/A

0DataRank · unranked

3 citations

Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa Glencer, Phoebe Miller, Rita A. Mukhtar +10 more

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

Cancers(2020)10.3390/cancers12061511

N/A

0DataRank · unranked

18 citations

Deep Hathi, Rita I. Freimanis, Rita A. Mukhtar, A. Jo Chien, Laura J. Esserman +4 more

Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study

Radiology(2023)10.1148/radiol.222733

N/A

0DataRank · unranked

91 citations

Laurel A. Habel, Ninah Achacoso, Diana S.M. Buist, Jason B. Cord, Laura J. Esserman +15 more

Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2− Patients

Journal of Breast Imaging(2020)10.1093/jbi/wbaa028

N/A

0DataRank · unranked

20 citations

Paul Kim, Wen Li, Fredrik Strand, Cody McHargue, Roy Harnish +8 more

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response

Tomography(2022)10.3390/tomography8020072

N/A

0DataRank · unranked

5 citations

Natsuko Onishi, Julia Carmona-Bozo, Wen Li, John Kornak, David C. Newitt +2 more

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer

Tomography(2022)10.3390/tomography8030099

N/A

0DataRank · unranked

7 citations

Wen Li, Natsuko Onishi, David C. Newitt, Jessica Gibbs, Lisa J. Wilmes +8 more

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial

Tomography(2022)10.3390/tomography8020058

N/A

0DataRank · unranked

13 citations

Jon A. Steingrimsson, David C. Newitt, Jessica Gibbs, Helga S. Marques, Patrick J. Bolan +5 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Cancers(2022)10.3390/cancers14184436

N/A

0DataRank · unranked

23 citations

Nu N. Le, Natsuko Onishi, David C. Newitt, Lisa J. Wilmes, Jessica Gibbs +15 more

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer(2021)10.1038/s41523-021-00233-9

N/A

0DataRank · unranked

23 citations

Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola M. Hylton +7 more

Denoising and Multiple Tissue Compartment Visualization of Multi‐b‐Valued Breast Diffusion MRI

Journal of Magnetic Resonance Imaging(2020)10.1002/jmri.27268

N/A

0DataRank · unranked

6 citations

Lisa J. Wilmes, Bonnie N. Joe, Natsuko Onishi, Vignesh A. Arasu, Nola M. Hylton +3 more

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy

Tomography(2020)10.18383/j.tom.2020.00009

N/A

0DataRank · unranked

11 citations

Vignesh A. Arasu, Fredrik Strand, Wen Li, Natsuko Onishi, Jessica Gibbs +6 more

Nola M. Hylton

Indexed papers

Top data-sharing exemplar

Papers